证券日报网讯 2月11日，安科生物发布公告称，公司及全资子公司安科恒益的阿托西班注射剂、丙酚替 诺福韦口服常释剂型拟中选国家集采1-8批协议期满品种接续采购，采购周期至2028年12月31日。 （文章来源：证券日报） ...

格隆汇2月11日丨安科生物(300009.SZ)公布，公司及全资子公司安徽安科恒益药业有限公司（简称"安科 恒益"）于近日参加了国家组织集采第1-8批协议期满品种接续采购的申报，根据国家组织集采药品协议 期满品种接续采购办公室（简称"接续采购办公室"）于2026年2月10日发布的《国家组织集采药品协议 期满品种接续采购拟中选结果表（LC-YPJX-2026-1）》显示，公司产品阿托西班注射剂及安科恒益产 品丙酚替诺福韦口服常释剂型在本次接续采购拟中选目录内。 ...

注：上述品种的拟中选价格及拟中标数量均以接续采购办公室发布的最终数 据为准。 二、本次拟中选产品对公司的影响 证券代码：300009 证券简称：安科生物 公告编号：2026-003 安徽安科生物工程（集团）股份有限公司 关于公司产品拟中选国家集采药品接续采购的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）及全资子公 司安徽安科恒益药业有限公司（以下简称"安科恒益"）于近日参加了国家组织 集采第 1-8 批协议期满品种接续采购的申报，根据国家组织集采药品协议期满品 种接续采购办公室（以下简称"接续采购办公室"）于 2026 年 2 月 10 日发布的 《国家组织集采药品协议期满品种接续采购拟中选结果表（LC-YPJX-2026-1）》 显示，公司产品阿托西班注射剂及安科恒益产品丙酚替诺福韦口服常释剂型在本 次接续采购拟中选目录内，现将相关情况公告如下： | 品种名称 | 适应症 | 规格 | 采购周期 | 拟供应区域 | | --- | --- | --- | --- | --- | | 阿托西班 注射 ...

证券日报网讯2月6日，安科生物（300009）在互动平台回答投资者提问时表示，公司生产经营一切正 常，不存在未及时披露的经营风险。目前公司在研产品的临床试验正在积极推进中，其中"HuA21注射 液"是公司自主研发的HER2靶点的一款新药，协同曲妥珠联用增加肿瘤抑制效果，前期探索性研究阶段 性数据呈现出较好的安全性和疗效，目前已顺利完成Ib/II期临床研究的受试者入组，将根据中期分析结 果计划开展III期临床研究，目前III期临床试验方案讨论会已经召开；"AK2024注射液"是公司开发的针 对HER2靶点的创新药物，目前正在开展I期临床试验，临床前研究表明，"AK2024注射液"可抑制HER2 阳性肿瘤细胞的增殖，在增强曲妥珠单抗对肿瘤生长的抑制作用方面，其协同效应明显优于帕妥珠单 抗；"HK010注射液"是公司开发的"PD-L1*4-1BB"双抗药物，目前完成II期临床试验的首例受试者入组 用药；"AK2017注射液"(重组人生长激素-Fc融合蛋白注射液)临床试验进展顺利，目前正在开展III期临 床试验；用于治疗呼吸道合胞病毒引起的儿童下呼吸道感染的"AK1012项目"(人干扰素α2b吸入用溶液) 已经完成I ...

Market Overview - The biopharmaceutical sector increased by 1.27% on February 3, with Wanzhe Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Stock Performance - Wanzhe Co., Ltd. (000534) closed at 30.65, with a rise of 10.01% and a trading volume of 313,500 shares, amounting to a transaction value of 921 million yuan [1] - Other notable performers included ST Weiming (002581) with a 5.01% increase, closing at 7.55, and Nearshore Protein (688137) with a 4.84% increase, closing at 44.20 [1] Capital Flow - The biopharmaceutical sector experienced a net outflow of 255 million yuan from institutional investors and 153 million yuan from retail investors, while retail investors saw a net inflow of 408 million yuan [2] - The capital flow for individual stocks showed that Wanzhe Co., Ltd. had a net outflow of 50.83 million yuan from institutional investors, while retail investors contributed a net inflow of 15.59 million yuan [3] Individual Stock Analysis - Eurolin Biotech (688319) had a net inflow of 21.61 million yuan from institutional investors, while ST Weiming (002581) saw a significant net inflow of 13.51 million yuan [3] - Conversely, major outflows were noted in Wanzhe Co., Ltd. and other stocks, indicating varied investor sentiment across the sector [3]

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

证券日报网讯1月26日，安科生物（300009）在互动平台回答投资者提问时表示，公司参股公司博生吉 公司创新药物的海外授权工作持续推进中，若有结果公司会通过合适的方式进行披露。公司持续关注包 括以AI平台技术为核心技术的相关公司。隆培促生长激素即将结束国家CDE的审评。 ...

Group 1 - The core point of the article is that Anke Bio has received the "High-tech Enterprise Certificate" from multiple government bodies in Anhui Province, which may enhance its market position and credibility in the industry [2] Group 2 - Anke Bio's wholly-owned subsidiary, Anhui Anke Hengyi Pharmaceutical Co., Ltd., is the entity that received the certification [2] - The certificate was jointly issued by the Anhui Provincial Department of Industry and Information Technology, the Anhui Provincial Department of Finance, and the State Taxation Administration of Anhui Province [2]

Core Viewpoint - Anke Bio (300009.SZ) has received a new High-tech Enterprise Certificate from the Anhui Provincial Department of Industry and Information Technology, Anhui Provincial Department of Finance, and the State Taxation Administration of Anhui Province for its wholly-owned subsidiary, Anhui Anke Hengyi Pharmaceutical Co., Ltd. This certification is a renewal following the expiration of the previous certificate [1]. Group 1 - Anke Hengyi has been recognized as a high-tech enterprise, which may enhance its credibility and competitive position in the pharmaceutical industry [1]. - The renewal of the high-tech enterprise certification indicates ongoing compliance with the standards set by the relevant authorities, reflecting the company's commitment to innovation and technology [1].

证券代码：300009 证券简称：安科生物 公告编号：2026-002 安徽安科生物工程（集团）股份有限公司 关于全资子公司通过高新技术企业认定的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）全资子公司 安徽安科恒益药业有限公司（以下简称"安科恒益"）于近日收到安徽省工业和 信息化厅、安徽省财政厅、国家税务总局安徽省税务局联合颁发的《高新技术企 业证书》，具体情况如下： 企业名称：安徽安科恒益药业有限公司 证书编号：GR202534002648 发证日期：2025 年 10 月 28 日 有效期：三年 本次高新技术企业认定系安科恒益原证书有效期满后进行的重新认定。根据 《中华人民共和国企业所得税法》等相关规定，安科恒益自通过高新技术企业认 定当年起，连续三年（2025 年至 2027 年）可继续享受国家关于高新技术企业的 相关税收优惠政策，即按 15%的税率缴纳企业所得税。安科恒益 2025 年度已按 照 15%的企业所得税税率进行纳税申报及预缴，本次通过高新技术企业认定事项 不会对公司 2025 年 ...